Michael Boler, DO
Cardiovascular Disease · Tupelo, MSNPI 1023305687
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 245 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 13.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,566, 2.4 times the $661 reported in 2019.
Across 245 payments — averaging $26.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$884
- Merck$757
- Novartis$543
- Abiomed$516
- AstraZeneca$352
- E.r. Squibb & Sons, L.L.C.$339
- plus $3K from 27 others
What the payments were for
- Food & beverage$6,370100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 23 | $884 |
| Merck | 41 | $757 |
| Novartis | 39 | $543 |
| Abiomed | 14 | $516 |
| AstraZeneca | 16 | $352 |
| E.r. Squibb & Sons, L.L.C. | 14 | $339 |
| W. L. Gore & Associates, Inc. | 9 | $326 |
| Inari Medical, Inc. | 6 | $300 |
| Boston Scientific | 7 | $280 |
| Thrombolex, Inc. | 2 | $240 |
| Cook Medical LLC | 4 | $226 |
| Boehringer Ingelheim | 10 | $219 |
| Amgen | 12 | $193 |
| Abbott | 3 | $192 |
| Lexicon Pharmaceuticals, Inc. | 7 | $136 |
| Esperion Therapeutics, Inc. | 8 | $135 |
| Pfizer | 5 | $100 |
| Bard Peripheral Vascular, Inc. | 1 | $97 |
| Terumo Medical Corporation | 2 | $93 |
| Janssen Scientific Affairs, LLC | 1 | $80 |
| Gilead | 5 | $77 |
| Astellas Pharma US Inc | 3 | $67 |
| Alnylam Pharmaceuticals Inc. | 3 | $58 |
| Scpharmaceuticals Inc. | 1 | $26 |
| Cardiva Medical, Inc. | 1 | $22 |
| Bayer | 1 | $20 |
| Celonova Biosciences, Inc. | 1 | $17 |
| Novo Nordisk | 1 | $17 |
| Bardy Diagnostics, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $13 |
| Akcea Therapeutics, Inc. | 1 | $12 |
| Lantheus Medical Imaging, Inc. | 1 | $11 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,370 in reported general payments places this provider in the 60th percentile of 144 cardiovascular disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 259 | $224,143 |
| EntrestoSacubitril/Valsartan | 116 | $102,293 |
| FarxigaDapagliflozin Propanediol | 80 | $74,796 |
| JardianceEmpagliflozin | 86 | $71,332 |
| XareltoRivaroxaban | 88 | $67,546 |
| Repatha SureclickEvolocumab | 52 | $44,314 |
| BrilintaTicagrelor | 52 | $30,676 |
| Praluent PenAlirocumab | 12 | $12,980 |
| VerquvoVericiguat | 14 | $10,877 |
| Rosuvastatin Calcium | 273 | $3,270 |
| Metoprolol Succinate | 318 | $3,163 |
| Ezetimibe | 160 | $3,123 |
| Ranolazine ErRanolazine | 46 | $3,043 |
| ClopidogrelClopidogrel Bisulfate | 255 | $2,039 |
| Atorvastatin Calcium | 268 | $1,761 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $100 | $224,143259 claims |
| AstraZenecaFarxiga, Brilinta | $352 | $105,471132 claims |
| NovartisEntresto | $543 | $102,293116 claims |
| Boehringer IngelheimJardiance | $219 | $71,33286 claims |
| Johnson & JohnsonXarelto | $13 | $67,54688 claims |
| MerckVerquvo | $757 | $10,87714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 144 cardiovascular disease providers in Mississippi.
Other cardiovascular disease in Tupelo
- Barry BertoletTupelo$469K
- Benjamin BlossomTupelo$7K
- Dharmesh PatelSouthaven$1.5M
- Donny StokesJackson$207K
- Mahmoud ZayedPascagoula$103K
- James BenslerJackson$64K
- Michael HallJackson$54K
- Hugo QuintanaPascagoula$48K
- Ediz TasanPascagoula$42K
- Lawrence LeaderHattiesburg$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.